Reduced moxifloxacin exposure in patients with tuberculosis and diabetes

Prevalence of diabetes mellitus (DM) in patients with tuberculosis (TB) is increasing and may negatively impact TB outcomes in patients with active disease [1]. Gastrointestinal problems, including gastroparesis, may result in delayed drug absorption or malabsorption in patients with DM, which may cause suboptimal drug exposure and poor outcome [2]. Studies on the pharmacokinetics of the first-line anti-TB drugs in patients with DM yielded conflicting results on low drug exposure [3–7]. Moxifloxacin is a potent bactericidal drug against Mycobacterium tuberculosis and is key for the treatment of multidrug-resistant tuberculosis (MDR)-TB [8].

Source: European Respiratory Journal - September 4, 2019 Category: Respiratory Medicine Authors: Dekkers, B. G. J., Bolhuis, M. S., ter Beek, L., de Lange, W. C. M., van der Werf, T. S., Alffenaar, J.-W. C., Akkerman, O. W. Tags: Original Articles: Research letters Source Type: research